Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was $40.45 for the day, up 6.84% from the previous closing price of $37.86. In other words, the price has increased by $6.84 from its previous closing price. On the day, 2.6 million shares were traded. NAMS stock price reached its highest trading level at $41.47 during the session, while it also had its lowest trading level at $37.505.
Ratios:
Our analysis of NAMS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 21.08 and its Current Ratio is at 21.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 25, 2025, initiated with a Overweight rating and assigned the stock a target price of $45.
On July 17, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $27.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $42.Citigroup initiated its Buy rating on June 17, 2025, with a $42 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 15 ’25 when Topper James N bought 660 shares for $23.70 per share. The transaction valued at 15,639 led to the insider holds 3,028,524 shares of the business.
Kooij Louise Frederika sold 150,000 shares of NAMS for $3,874,017 on Sep 09 ’25. The Chief Accounting Officer now owns 15,000 shares after completing the transaction at $25.83 per share. On Sep 08 ’25, another insider, Topper James N, who serves as the Director of the company, bought 1,260 shares for $24.99 each. As a result, the insider paid 31,487 and bolstered with 3,027,864 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 4555821056 and an Enterprise Value of 3816987136. For the stock, the TTM Price-to-Sale (P/S) ratio is 71.17 while its Price-to-Book (P/B) ratio in mrq is 5.85. Its current Enterprise Value per Revenue stands at 59.635 whereas that against EBITDA is -22.113.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.02, which has changed by 0.9894903 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $39.76, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 48.02%, while the 200-Day Moving Average is calculated to be 81.81%.
Shares Statistics:
NAMS traded an average of 957.93K shares per day over the past three months and 1404770 shares per day over the past ten days. A total of 112.51M shares are outstanding, with a floating share count of 74.54M. Insiders hold about 33.82% of the company’s shares, while institutions hold 61.53% stake in the company. Shares short for NAMS as of 1759190400 were 7640225 with a Short Ratio of 7.98, compared to 1756425600 on 7497579. Therefore, it implies a Short% of Shares Outstanding of 7640225 and a Short% of Float of 8.09.
Earnings Estimates
The market rating of NewAmsterdam Pharma Company NV (NAMS) is currently shaped by the ongoing analysis conducted by 12.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.26 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$0.94 and -$1.45 for the fiscal current year, implying an average EPS of -$1.2. EPS for the following year is -$1.72, with 10.0 analysts recommending between -$1.12 and -$2.52.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $46.21M, while the lowest revenue estimate was $18.99M, resulting in an average revenue estimate of $27.2M. In the same quarter a year ago, actual revenue was $43.39M
